Express Scripts to offer a way to lower insulin costs

As insulin prices continue to skyrocket one insurance company announced plans to cap monthly insulin costs at $25

As insulin prices continue to skyrocket one insurance company announced plans to cap monthly insulin costs at $25

Health insurer Cigna Corp on Wednesday launched a program aimed at ensuring some diabetes patients pay no more than $25 for a 30-day supply of insulin. Typically, Cigna and Express Scripts customers who use insulin pay about $41.50 out of pocket for a 30-day supply.

The country's largest pharmacy benefit manager - itself acquired previous year by one of the country's biggest health insurers - is introducing a program to cap out-of-pocket costs for diabetes patients who rely on insulin.

The program is only available to members who participate in non-government-funded pharmacy plans managed by Express Scripts, including Cigna and other plans. Cigna acquired Express Scripts, the largest United States pharmacy benefit management company, in December.

One report found a jump in prices for all types of insulin and insulin products.

Vials of insulin belonging to David Burns, 38, who has type 1 diabetes, are photographed in his home in North London on February 24, 2019.

Guardiola's Manchester City charge towards the quadruple
Liverpool can return to the top of the table if they beat Southampton on Friday night. And Warnock said: "I don't think they could've given us any more".

At a US House of Representatives subcommittee hearing on insulin pricing Tuesday, Aaron Kowalski, chief mission officer of JDRF, a nonprofit diabetes research funding organization, called for the elimination of rebates - which make up more than 70% of the list price of insulin - from the drug reimbursement system.

"For people with diabetes, insulin can be as essential as air", Dr. The company said the cap would reduce out-of-pocket payments for insulin by almost 40%. Health plan sponsors, such as employers and labor unions, will have to opt-in to an out-of-pocket cap program in order for patients to benefit from it.

The annual cost of insulin for treating a type 1 diabetes patient in the United States almost doubled to $5,705 in 2016 from $2,864 in 2012, according to a recent study.

"Every part of the industry has a role to play in lowering prescription drug prices". Prices for the most commonly prescribed insulins have increased by more than 700% over the last 20 years, accounting for inflation.

Latest News